Earnings call transcript: Sanara MedTech sees revenue surge in Q2 2025

Sanara MedTech Inc. (SMTI) reported a robust Q2 2025, with net revenue climbing 28% year-over-year to $25.8 million and achieving a net income of $500,000, reversing a $2.7 million loss from the prior year. This strong performance, driven by sales in soft tissue and bone fusion products, yielded a 91.17% gross profit margin and a 350% increase in consolidated Adjusted EBITDA to $2.7 million. The positive earnings prompted an 8.45% surge in SMTI's stock in premarket trading. Concurrently, the company is exploring strategic alternatives for its Tissue Health Plus (THP) segment to preserve capital, signaling a focus on its profitable Surgical division and aiming to maximize shareholder value.

Analysis

Sanara MedTech (SMTI) delivered a strong Q2 2025, marked by a significant operational turnaround and a pivotal strategic shift. The company reported a 28% year-over-year revenue increase to $25.8 million, driven by robust performance in its core Surgical segment, where soft tissue and bone fusion product sales grew 28% and 25% respectively. This top-line growth, combined with an industry-leading gross profit margin of 91.17%, enabled the company to reverse a prior-year loss of $2.7 million to achieve a net income of $500,000. Consequently, consolidated adjusted EBITDA surged 350% to $2.7 million. The most critical development is the formal process to evaluate strategic alternatives for the cash-intensive Tissue Health Plus (THP) segment, which posted a $2.5 million net loss. Management's commitment to preserving capital by ceasing material cash investments in THP after 2025 signals a clear focus on its profitable Surgical division. While the positive results drove an 8.45% premarket stock surge, a dichotomy exists in its valuation; an internal model suggests it is overvalued, yet analyst price targets of $45-$53 imply substantial upside, reflecting the market's positive reception to the company's refined focus on its high-growth, high-margin core business.

Key Decisions for Investors

• Investors should view the strategic review of the Tissue Health Plus (THP) segment as a significant de-risking catalyst; any resulting sale or partnership could eliminate a major cash drain and unlock shareholder value.
• While fundamentals are strong, the stock's 1.26 beta indicates high volatility, and investors should weigh the conflicting signals of a potentially high valuation against bullish analyst price targets before initiating or adding to a position.
• Monitor the company’s ability to sustain growth in its core Surgical segment by tracking the expansion of its distributor network and penetration into new healthcare facilities, as these are the primary drivers of future profitability.